SAB Biotherapeutics, Inc.
NASDAQTotal Valuation
SAB Biotherapeutics, Inc. carries a market capitalization of 338.47M, placing it among publicly traded companies globally. Its enterprise value stands at 228.12M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 338.47M |
| Enterprise Value | 228.12M |
Share Statistics
SAB Biotherapeutics, Inc. currently has 83.49M shares outstanding.
| Shares Outstanding | 83.49M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
SAB Biotherapeutics, Inc. trades at a trailing price-to-earnings ratio of 2.84.
| PE Ratio | 2.84 |
| PS Ratio | N/A |
| PB Ratio | 1.52 |
| P/TBV Ratio | 1.52 |
| P/FCF Ratio | -5.44 |
| P/OCF Ratio | -3.47 |
Financial Position
SAB Biotherapeutics, Inc. maintains a current ratio of 9.22, meaning it holds 9.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 2.39, indicating elevated leverage, while an interest coverage ratio of -296.79 demonstrates limited ability to service its debt obligations.
| Current Ratio | 9.22 |
| Quick Ratio | 8.93 |
| Debt / Equity | 2.39 |
| Debt / EBITDA | -0.07 |
| Interest Coverage | -296.79 |
Financial Efficiency
| Return on Equity (ROE) | -11.27 |
| Return on Assets (ROA) | -9.52 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | 17.89 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
SAB Biotherapeutics, Inc.'s stock has gained approximately 63.87665% over the past 52 weeks. The 50-day moving average sits at 3.73, while the 200-day moving average is 3.82.
| Beta (5Y) | N/A |
| 52-Week Price Change | 63.87665% |
| 50-Day Moving Average | 3.73 |
| 200-Day Moving Average | 3.82 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -68.71M, while operating income came in at -71.82M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -71.82M |
| Pretax Income | -12.78M |
| Net Income | -12.78M |
| EBITDA | -68.71M |
| EBIT | -71.82M |
| Earnings Per Share (EPS) | -0.18 |
Balance Sheet
SAB Biotherapeutics, Inc. holds 102.63M in cash and equivalents against 5.13M in total debt, resulting in a net debt position of -8.27M. Total book value stands at 214.79M, with working capital of 96.23M providing operational flexibility.
| Cash & Cash Equivalents | 102.63M |
| Total Debt | 5.13M |
| Net Debt | -8.27M |
| Equity (Book Value) | 214.79M |
| Book Value Per Share | 2.57 |
| Working Capital | 96.23M |
Cash Flow
SAB Biotherapeutics, Inc. produced -53.94M in operating cash flow over the past twelve months. After subtracting -3.50M in capital expenditures, free cash flow totaled -57.44M - equivalent to -1.20 per share.
| Operating Cash Flow | -53.94M |
| Capital Expenditures | -3.50M |
| Free Cash Flow | -57.44M |
| FCF Per Share | -1.20 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -80.13 |
| FCF Yield | -18.37 |
Stock Splits
SAB Biotherapeutics, Inc.'s most recent stock split took place on January 5, 2024 with a 10:1 split ratio.
| Last Split Date | 1/5/2024 |
| Split Ratio | 10:1 |
Scores
SAB Biotherapeutics, Inc. posts an Altman Z-Score of 6.94, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 6.94 |